Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Amplification of the mutation-carrying BRCA2 allele promotes RAD51 loading and PARP inhibitor resistance in the absence of reversion mutations.

Park PH, Yamamoto TM, Li H, Alcivar AL, Xia B, Wang Y, Bernhardy AJ, Turner KM, Kossenkov AV, Watson ZL, Behbakht K, Casadei S, Swisher EM, Mischel PS, Johnson N, Bitler BG.

Mol Cancer Ther. 2019 Oct 1. pii: molcanther.0256.2019. doi: 10.1158/1535-7163.MCT-17-0256. [Epub ahead of print]

PMID:
31575654
2.

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.

Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA III, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM.

J Natl Compr Canc Netw. 2019 Aug 1;17(8):896-909. doi: 10.6004/jnccn.2019.0039.

PMID:
31390583
3.

Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma.

Adams CL, Dimitrova I, Post MD, Gibson L, Spillman MA, Behbakht K, Bradford AP.

Exp Mol Pathol. 2019 Oct;110:104284. doi: 10.1016/j.yexmp.2019.104284. Epub 2019 Jul 10.

PMID:
31301306
4.

Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells.

Ramzan AA, Bitler BG, Hicks D, Barner K, Qamar L, Behbakht K, Powell T, Jansson T, Wilson H.

Mol Cell Biochem. 2019 Nov;461(1-2):37-46. doi: 10.1007/s11010-019-03586-9. Epub 2019 Jul 10.

PMID:
31292831
5.

Activation of Wnt signaling promotes olaparib resistant ovarian cancer.

Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, Bitler BG.

Mol Carcinog. 2019 Oct;58(10):1770-1782. doi: 10.1002/mc.23064. Epub 2019 Jun 10.

PMID:
31219654
6.

Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.

Moroney MR, Davies KD, Wilberger AC, Sheeder J, Post MD, Berning AA, Fisher C, Lefkowits C, Guntupalli SR, Behbakht K, Corr BR.

Gynecol Oncol. 2019 Jun;153(3):517-520. doi: 10.1016/j.ygyno.2019.03.100. Epub 2019 Mar 22.

PMID:
30910249
7.

Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel.

Breed C, Hicks DA, Webb PG, Galimanis CE, Bitler BG, Behbakht K, Baumgartner HK.

Mol Cancer Res. 2019 Mar;17(3):741-750. doi: 10.1158/1541-7786.MCR-18-0451. Epub 2019 Jan 3.

PMID:
30606772
8.

CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer.

Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Post MD, Berning AA, Spillman MA, Behbakht K, Bitler BG.

Oncogenesis. 2018 Nov 26;7(11):92. doi: 10.1038/s41389-018-0103-1.

9.

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.

Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ.

JAMA Oncol. 2019 Jan 1;5(1):e183773. doi: 10.1001/jamaoncol.2018.3773. Epub 2019 Jan 10.

PMID:
30347019
10.

Society of Gynecologic Oncology 2018 Annual Meeting on Women's Cancer: Meeting report.

Rauh-Hain JA, Brewster WR, Behbakht K.

Gynecol Oncol. 2018 Nov;151(2):e7-e9. doi: 10.1016/j.ygyno.2018.08.019. Epub 2018 Aug 24. No abstract available.

PMID:
30146111
11.

Minority Race Predicts Treatment by Non-gynecologic Oncologists in Women with Gynecologic Cancer.

Ramzan AA, Behbakht K, Corr BR, Sheeder J, Guntupalli SR.

Ann Surg Oncol. 2018 Nov;25(12):3685-3691. doi: 10.1245/s10434-018-6694-0. Epub 2018 Aug 13.

PMID:
30105439
12.

Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer.

Behbakht K, Cohn DE, Straughn JM Jr.

Gynecol Oncol. 2018 Oct;151(1):4-5. doi: 10.1016/j.ygyno.2018.07.019. Epub 2018 Jul 30. No abstract available.

PMID:
30068488
13.

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.

Niu H, Shin H, Gao F, Zhang J, Bahamon B, Danaee H, Melichar B, Schilder RJ, Coleman RL, Falchook G, Adenis A, Behbakht K, DeMichele A, Dees EC, Perez K, Matulonis U, Sawrycki P, Huebner D, Ecsedy J.

EBioMedicine. 2017 Nov;25:50-57. doi: 10.1016/j.ebiom.2017.10.015. Epub 2017 Oct 16.

14.

PARP inhibitors: Clinical utility and possibilities of overcoming resistance.

Bitler BG, Watson ZL, Wheeler LJ, Behbakht K.

Gynecol Oncol. 2017 Dec;147(3):695-704. doi: 10.1016/j.ygyno.2017.10.003. Epub 2017 Oct 14. Review.

15.

A method for extracting and characterizing RNA from urine: For downstream PCR and RNAseq analysis.

Zhou K, Spillman MA, Behbakht K, Komatsu JM, Abrahante JE, Hicks D, Schotl B, Odean E, Jones KL, Graner MW, Bemis LT.

Anal Biochem. 2017 Nov 1;536:8-15. doi: 10.1016/j.ab.2017.08.003. Epub 2017 Aug 10.

16.

Statistical performance of image cytometry for DNA, lipids, cytokeratin, & CD45 in a model system for circulation tumor cell detection.

Futia GL, Schlaepfer IR, Qamar L, Behbakht K, Gibson EA.

Cytometry A. 2017 Jul;91(7):662-674. doi: 10.1002/cyto.a.23144. Epub 2017 Jun 13.

17.

Sexual and Marital Dysfunction in Women With Gynecologic Cancer.

Guntupalli SR, Sheeder J, Ioffe Y, Tergas A, Wright JD, Davidson SA, Behbakht K, Flink DM.

Int J Gynecol Cancer. 2017 Mar;27(3):603-607. doi: 10.1097/IGC.0000000000000906.

PMID:
28129243
18.

A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance.

Dimberg LY, Towers CG, Behbakht K, Hotz TJ, Kim J, Fosmire S, Porter CC, Tan AC, Thorburn A, Ford HL.

Mol Cancer Res. 2017 Apr;15(4):382-394. doi: 10.1158/1541-7786.MCR-16-0234. Epub 2017 Jan 20.

19.

Disparities in standard of care treatment and associated survival decrement in patients with locally advanced cervical cancer.

Robin TP, Amini A, Schefter TE, Behbakht K, Fisher CM.

Gynecol Oncol. 2016 Nov;143(2):319-325. doi: 10.1016/j.ygyno.2016.09.009. Epub 2016 Sep 16.

PMID:
27640961
20.

Claudin-4 activity in ovarian tumor cell apoptosis resistance and migration.

Hicks DA, Galimanis CE, Webb PG, Spillman MA, Behbakht K, Neville MC, Baumgartner HK.

BMC Cancer. 2016 Oct 11;16(1):788.

21.

Brachytherapy should not be omitted when treating locally advanced neuroendocrine cervical cancer with definitive chemoradiation therapy.

Robin TP, Amini A, Schefter TE, Behbakht K, Fisher CM.

Brachytherapy. 2016 Nov - Dec;15(6):845-850. doi: 10.1016/j.brachy.2016.08.007. Epub 2016 Oct 4.

PMID:
27720204
22.

Bevacizumab induced hypertension in gynecologic cancer: Does it resolve after completion of therapy?

Corr BR, Breed C, Sheeder J, Weisdack S, Behbakht K.

Gynecol Oncol Rep. 2016 Jun 16;17:65-8. doi: 10.1016/j.gore.2016.06.002. eCollection 2016 Aug.

23.

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Morgan RJ Jr, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M.

J Natl Compr Canc Netw. 2016 Sep;14(9):1134-63.

PMID:
27587625
24.

Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia.

Osborne RJ, Filiaci VL, Schink JC, Mannel RS, Behbakht K, Hoffman JS, Spirtos NM, Chan JK, Tidy JA, Miller DS.

Obstet Gynecol. 2016 Sep;128(3):535-42. doi: 10.1097/AOG.0000000000001554.

25.

Influence of Gelatin-Thrombin Matrix Tissue Sealant on Bacterial Colony Formation and Risk of Pelvic Infection.

Jarrett MJ, Vázquez-Torres A, Frank DN, McCollister BD, Henthorn PK, Ir D, Sheeder J, Guy MS, Anwar HQ, Behbakht K.

Infect Dis Obstet Gynecol. 2016;2016:2649708. doi: 10.1155/2016/2649708. Epub 2016 Apr 21.

26.

Factors Impacting Use of Robotic Surgery for Treatment of Endometrial Cancer in the United States.

Blake EA, Sheeder J, Behbakht K, Guntupalli SR, Guy MS.

Ann Surg Oncol. 2016 Oct;23(11):3744-3748. doi: 10.1245/s10434-016-5252-x. Epub 2016 May 12.

PMID:
27172774
27.

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.

Myers AP, Filiaci VL, Zhang Y, Pearl M, Behbakht K, Makker V, Hanjani P, Zweizig S, Burke JJ 2nd, Downey G, Leslie KK, Van Hummelen P, Birrer MJ, Fleming GF.

Gynecol Oncol. 2016 Apr;141(1):43-8. doi: 10.1016/j.ygyno.2016.02.025.

28.

Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.

Guy MS, Qamar L, Behbakht K, Post MD, Sheeder J, Sartorius CA, Spillman MA.

Gynecol Oncol. 2016 Mar;140(3):518-26. doi: 10.1016/j.ygyno.2015.12.022. Epub 2015 Dec 28.

PMID:
26731726
29.

Association Between Preoperative Chemotherapy and Postoperative Complications in Patients Undergoing Surgery for Ovarian Cancer.

Doo DW, Guy MS, Behbakht K, Davidson SA, Sheeder J, Guntupalli SR.

Ann Surg Oncol. 2016 Mar;23(3):968-74. doi: 10.1245/s10434-015-4955-8. Epub 2015 Nov 5.

PMID:
26542594
30.

Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer.

Corr BR, Finlay-Schultz J, Rosen RB, Qamar L, Post MD, Behbakht K, Spillman MA, Sartorius CA.

Int J Gynecol Cancer. 2015 Nov;25(9):1565-73. doi: 10.1097/IGC.0000000000000553.

31.

Comparative outcomes in older and younger women undergoing laparotomy or robotic surgical staging for endometrial cancer.

Guy MS, Sheeder J, Behbakht K, Wright JD, Guntupalli SR.

Am J Obstet Gynecol. 2016 Mar;214(3):350.e1-350.e10. doi: 10.1016/j.ajog.2015.09.085. Epub 2015 Nov 18.

PMID:
26433173
32.

Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

Zighelboim I, Ali S, Lankes HA, Backes F, Moore K, Mutch D, Robison K, Behbakht K, Waggoner S, Ghebre RG, Pearl M, Ramirez NC, Goodfellow P.

Gynecol Oncol. 2015 Sep;138(3):614-9. doi: 10.1016/j.ygyno.2015.06.038. Epub 2015 Jul 3.

33.

Awareness of symptoms and risk factors of ovarian cancer in a population of women and healthcare providers.

Goldstein CL, Susman E, Lockwood S, Medlin EE, Behbakht K.

Clin J Oncol Nurs. 2015 Apr;19(2):206-12. doi: 10.1188/15.CJON.206-212.

PMID:
25840386
34.

Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.

Hensley ML, Miller A, O'Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H.

J Clin Oncol. 2015 Apr 1;33(10):1180-5. doi: 10.1200/JCO.2014.58.3781. Epub 2015 Feb 23.

35.

Comparative Surgical Outcomes for Endometrial Cancer Patients 65 Years Old or Older Staged With Robotics or Laparotomy.

Doo DW, Guntupalli SR, Corr BR, Sheeder J, Davidson SA, Behbakht K, Jarrett MJ, Guy MS.

Ann Surg Oncol. 2015 Oct;22(11):3687-94. doi: 10.1245/s10434-015-4428-0. Epub 2015 Feb 12.

PMID:
25672563
36.

Association between gelatin-thrombin matrix use and abscesses in women undergoing pelvic surgery.

Anderson CK, Medlin E, Ferriss AF, Sheeder J, Davidson S, Gibbs R, Behbakht K, Guntupalli SR.

Obstet Gynecol. 2014 Sep;124(3):589-95. doi: 10.1097/AOG.0000000000000406.

PMID:
25162261
37.

Anti-ma2 paraneoplastic encephalitis in association with recurrent cervical cancer.

Ney DE, Messersmith W, Behbakht K.

J Clin Neurol. 2014 Jul;10(3):262-6. doi: 10.3988/jcn.2014.10.3.262. Epub 2014 Jul 3.

38.

A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study.

Alvarez RD, Sill MW, Davidson SA, Muller CY, Bender DP, DeBernardo RL, Behbakht K, Huh WK.

Gynecol Oncol. 2014 Jun;133(3):433-8. doi: 10.1016/j.ygyno.2014.03.571. Epub 2014 Apr 4.

39.

Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer.

Kim Y, Guntupalli SR, Lee SJ, Behbakht K, Theodorescu D, Lee JK, Diamond JR.

PLoS One. 2014 Feb 5;9(2):e86532. doi: 10.1371/journal.pone.0086532. eCollection 2014.

40.

Gynecologic biopsy for molecular profiling: a review for the interventional radiologist.

Corr BR, Behbakht K, Spillman MA.

Semin Intervent Radiol. 2013 Dec;30(4):417-24. doi: 10.1055/s-0033-1359738. Review.

41.

Outcomes of women with atypical glandular cells on preoperative cytology and endometrial cancer.

Guy MS, Cheng G, Post MD, Spillman MA, Behbakht K, Davidson S, Sheeder J, Guntupalli SR.

Int J Gynecol Cancer. 2014 Feb;24(2):266-71. doi: 10.1097/IGC.0000000000000027.

PMID:
24401985
42.

Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer.

Anderson CK, Wallace S, Guiahi M, Sheeder J, Behbakht K, Spillman MA.

Int J Gynecol Cancer. 2013 Mar;23(3):417-21. doi: 10.1097/IGC.0b013e3182849dba. Review.

PMID:
23385282
43.

ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer.

Matulonis UA, Lee J, Lasonde B, Tew WP, Yehwalashet A, Matei D, Behbakht K, Grothusen J, Fleming G, Lee NK, Arnott J, Bray MR, Fletcher G, Brokx RD, Castonguay V, Mackay H, Sidor CF, Oza AM.

Eur J Cancer. 2013 Jan;49(1):121-31. doi: 10.1016/j.ejca.2012.07.020. Epub 2012 Aug 21.

PMID:
22921155
44.

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.

Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL.

Oncogene. 2013 Mar 14;32(11):1341-50. doi: 10.1038/onc.2012.164. Epub 2012 May 14. Review.

45.

Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer.

Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht K.

Gynecol Oncol. 2012 May;125(2):451-7. doi: 10.1016/j.ygyno.2012.02.007. Epub 2012 Feb 12.

46.

Novel TP53 gene mutation and correlation with p53 immunohistochemistry in a mixed epithelial carcinoma of the endometrium.

Sholl AB, Aisner DL, Behbakht K, Post MD.

Gynecol Oncol Case Rep. 2012 Oct 26;3:11-3. doi: 10.1016/j.gynor.2012.10.005. eCollection 2012.

47.

Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Stashwick C, Post MD, Arruda JS, Spillman MA, Behbakht K, Davidson SA, Kelly MG.

Int J Gynecol Cancer. 2011 Nov;21(8):1422-7. doi: 10.1097/IGC.0b013e31822c7704.

PMID:
21997170
48.

Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells.

Wang Y, Sheng Q, Spillman MA, Behbakht K, Gu H.

Oncogene. 2012 May 17;31(20):2512-20. doi: 10.1038/onc.2011.435. Epub 2011 Sep 26.

49.

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.

Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK.

Gynecol Oncol. 2011 Oct;123(1):19-26. doi: 10.1016/j.ygyno.2011.06.022. Epub 2011 Jul 12.

50.

Lobular endocervical glandular hyperplasia with extensive mucinous differentiation of endometrium and endometrial mucinous adenocarcinoma in situ: a case report and review of literature.

Dinges MM, Jaggessarsingh D, Petersen TH, Behbakht K, Singh M.

Gynecol Oncol. 2011 Sep;122(3):686-8. doi: 10.1016/j.ygyno.2011.05.006. Epub 2011 May 24. No abstract available.

PMID:
21605894

Supplemental Content

Loading ...
Support Center